Latanoprost Ciclum

Latanoprost, the active ingredient in Latanoprost Ciclum, is a prostaglandin analog presented as an ophthalmic solution for ocular use. It treats primary open-angle glaucoma and ocular hypertension in adults.

GNH USA supplies Latanoprost Ciclum as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latanoprost is indicated for ocular conditions that require reduction of intra‑ocular pressure.

- Primary open‑angle glaucoma: lowers intra‑ocular pressure to slow visual field loss. - Ocular hypertension: reduces intra‑ocular pressure to prevent progression to glaucoma. - Secondary open‑angle glaucoma: helps control pressure when other therapies are insufficient.

Latanoprost may cause ocular and systemic reactions.

Common Side Effects: - Eye redness: mild conjunctival hyperemia. - Increased eyelash growth: longer, thicker lashes. - Iris darkening: gradual pigmentation change. - Eye irritation: burning or stinging sensation. - Blurred vision: transient visual disturbance. - Foreign body sensation: feeling of grit in the eye.

Serious or Rare Side Effects: - Severe allergic reaction: swelling, rash, or difficulty breathing. - Uveitis: inflammation of the uveal tract. - Macular edema: fluid accumulation in the retina. - Paradoxical increase in intra‑ocular pressure. - Corneal ulcer or keratitis. - Persistent eye pain or vision loss.

Before using Latanoprost, consider the following safety measures.

- Monitor intra‑ocular pressure: assess response after initiation. - Assess for ocular infections: avoid use if active infection is present. - Evaluate hypersensitivity: discontinue if allergic signs appear. - Use with caution in corneal disease: may exacerbate epithelial defects. - Avoid in active ocular inflammation: could worsen condition. - Store at room temperature: keep in original container, protect from moisture and light.

Latanoprost can interact with other ophthalmic and systemic agents.

Major Interactions (Avoid): - Concomitant prostaglandin analogs: increased risk of ocular side effects. - Ophthalmic steroids: may reduce Latanoprost efficacy. - Non‑steroidal anti‑inflammatory eye drops: potential for heightened inflammation.

Moderate Interactions (Monitor Closely): - Systemic beta‑blockers: additive hypotensive effect. - Systemic prostaglandin analogs: possible increased systemic exposure. - Contact lens solutions: may affect drug stability and absorption.